PubMed:11159917 JSONTXT

Annnotations TAB JSON ListView MergeView

    sentences

    {"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":151},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":152,"end":345},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":346,"end":604},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":605,"end":949},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":950,"end":1313},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":1314,"end":1487},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":1488,"end":1801},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1802,"end":2130},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":151},"obj":"Sentence"},{"id":"T2","span":{"begin":152,"end":345},"obj":"Sentence"},{"id":"T3","span":{"begin":346,"end":604},"obj":"Sentence"},{"id":"T4","span":{"begin":605,"end":949},"obj":"Sentence"},{"id":"T5","span":{"begin":950,"end":1313},"obj":"Sentence"},{"id":"T6","span":{"begin":1314,"end":1487},"obj":"Sentence"},{"id":"T7","span":{"begin":1488,"end":1801},"obj":"Sentence"},{"id":"T8","span":{"begin":1802,"end":2130},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":151},"obj":"Sentence"},{"id":"T2","span":{"begin":152,"end":345},"obj":"Sentence"},{"id":"T3","span":{"begin":346,"end":604},"obj":"Sentence"},{"id":"T4","span":{"begin":605,"end":949},"obj":"Sentence"},{"id":"T5","span":{"begin":950,"end":1313},"obj":"Sentence"},{"id":"T6","span":{"begin":1314,"end":1487},"obj":"Sentence"},{"id":"T7","span":{"begin":1488,"end":1801},"obj":"Sentence"},{"id":"T8","span":{"begin":1802,"end":2130},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    Glycosmos6-GlycoEpitope

    {"project":"Glycosmos6-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":2091,"end":2106},"obj":"http://www.glycoepitope.jp/epitopes/EP0086"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    GlycoBiology-PACDB

    {"project":"GlycoBiology-PACDB","denotations":[{"id":"_T1","span":{"begin":72,"end":99},"obj":"http://acgg.asia/db/diseases/pacdb/lec?ids=LEC569"},{"id":"_T2","span":{"begin":72,"end":99},"obj":"http://acgg.asia/db/diseases/pacdb/lec?ids=LEC520"},{"id":"_T3","span":{"begin":172,"end":199},"obj":"http://acgg.asia/db/diseases/pacdb/lec?ids=LEC569"},{"id":"_T4","span":{"begin":172,"end":199},"obj":"http://acgg.asia/db/diseases/pacdb/lec?ids=LEC520"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    GlycoBiology-FMA

    {"project":"GlycoBiology-FMA","denotations":[{"id":"_T1","span":{"begin":79,"end":86},"obj":"FMAID:178366"},{"id":"_T2","span":{"begin":100,"end":112},"obj":"FMAID:167256"},{"id":"_T3","span":{"begin":100,"end":112},"obj":"FMAID:62925"},{"id":"_T4","span":{"begin":127,"end":139},"obj":"FMAID:167256"},{"id":"_T5","span":{"begin":127,"end":139},"obj":"FMAID:62925"},{"id":"_T6","span":{"begin":179,"end":186},"obj":"FMAID:178366"},{"id":"_T7","span":{"begin":265,"end":278},"obj":"FMAID:166831"},{"id":"_T8","span":{"begin":273,"end":278},"obj":"FMAID:68646"},{"id":"_T9","span":{"begin":273,"end":278},"obj":"FMAID:169002"},{"id":"_T10","span":{"begin":282,"end":289},"obj":"FMAID:166033"},{"id":"_T11","span":{"begin":282,"end":289},"obj":"FMAID:54527"},{"id":"_T12","span":{"begin":282,"end":289},"obj":"FMAID:150783"},{"id":"_T13","span":{"begin":323,"end":330},"obj":"FMAID:67257"},{"id":"_T14","span":{"begin":323,"end":330},"obj":"FMAID:165447"},{"id":"_T15","span":{"begin":356,"end":368},"obj":"FMAID:62925"},{"id":"_T16","span":{"begin":356,"end":368},"obj":"FMAID:167256"},{"id":"_T17","span":{"begin":570,"end":580},"obj":"FMAID:166248"},{"id":"_T18","span":{"begin":570,"end":580},"obj":"FMAID:166257"},{"id":"_T19","span":{"begin":570,"end":580},"obj":"FMAID:61983"},{"id":"_T20","span":{"begin":570,"end":580},"obj":"FMAID:61986"},{"id":"_T21","span":{"begin":1029,"end":1041},"obj":"FMAID:62925"},{"id":"_T22","span":{"begin":1029,"end":1041},"obj":"FMAID:167256"},{"id":"_T23","span":{"begin":1846,"end":1858},"obj":"FMAID:212684"},{"id":"_T24","span":{"begin":1846,"end":1858},"obj":"FMAID:200942"},{"id":"_T25","span":{"begin":1851,"end":1858},"obj":"FMAID:146300"},{"id":"_T26","span":{"begin":1851,"end":1858},"obj":"FMAID:50594"},{"id":"_T27","span":{"begin":1894,"end":1902},"obj":"FMAID:167180"},{"id":"_T28","span":{"begin":1932,"end":1957},"obj":"FMAID:82786"},{"id":"_T29","span":{"begin":1932,"end":1957},"obj":"FMAID:196780"},{"id":"_T30","span":{"begin":1996,"end":2010},"obj":"FMAID:196730"},{"id":"_T31","span":{"begin":1996,"end":2010},"obj":"FMAID:82741"},{"id":"_T32","span":{"begin":2091,"end":2098},"obj":"FMAID:165191"},{"id":"_T33","span":{"begin":2091,"end":2098},"obj":"FMAID:67110"},{"id":"_T34","span":{"begin":2091,"end":2106},"obj":"FMAID:167405"},{"id":"_T35","span":{"begin":2091,"end":2106},"obj":"FMAID:63023"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    uniprot-human

    {"project":"uniprot-human","denotations":[{"id":"T1","span":{"begin":834,"end":846},"obj":"http://www.uniprot.org/uniprot/Q99484"},{"id":"T2","span":{"begin":1239,"end":1251},"obj":"http://www.uniprot.org/uniprot/Q99484"},{"id":"T3","span":{"begin":1587,"end":1599},"obj":"http://www.uniprot.org/uniprot/Q99484"},{"id":"T4","span":{"begin":1660,"end":1671},"obj":"http://www.uniprot.org/uniprot/Q99484"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    uniprot-mouse

    {"project":"uniprot-mouse","denotations":[{"id":"T1","span":{"begin":834,"end":846},"obj":"http://www.uniprot.org/uniprot/P38649"},{"id":"T2","span":{"begin":1239,"end":1251},"obj":"http://www.uniprot.org/uniprot/P38649"},{"id":"T3","span":{"begin":1587,"end":1599},"obj":"http://www.uniprot.org/uniprot/P38649"},{"id":"T4","span":{"begin":1660,"end":1671},"obj":"http://www.uniprot.org/uniprot/P38649"},{"id":"T5","span":{"begin":1095,"end":1098},"obj":"http://www.uniprot.org/uniprot/Q61024"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    GlycoBiology-NCBITAXON

    {"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T1","span":{"begin":72,"end":97},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/126283"},{"id":"T2","span":{"begin":87,"end":92},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/184751"},{"id":"T3","span":{"begin":172,"end":197},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/126283"},{"id":"T4","span":{"begin":187,"end":192},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/184751"},{"id":"T5","span":{"begin":244,"end":248},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/9973"},{"id":"T6","span":{"begin":273,"end":278},"obj":"http://purl.bioontology.org/ontology/STY/T025"},{"id":"T7","span":{"begin":920,"end":940},"obj":"http://purl.bioontology.org/ontology/STY/T039"},{"id":"T8","span":{"begin":1302,"end":1304},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/152839"},{"id":"T9","span":{"begin":1517,"end":1519},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/152839"},{"id":"T10","span":{"begin":1530,"end":1532},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/152839"},{"id":"T11","span":{"begin":1883,"end":1893},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/608684"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    GO-BP

    {"project":"GO-BP","denotations":[{"id":"T1","span":{"begin":24,"end":37},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T2","span":{"begin":331,"end":344},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T3","span":{"begin":775,"end":788},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T4","span":{"begin":899,"end":912},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T5","span":{"begin":1078,"end":1091},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T6","span":{"begin":1127,"end":1140},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T7","span":{"begin":1272,"end":1285},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T8","span":{"begin":384,"end":396},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T9","span":{"begin":1761,"end":1773},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T10","span":{"begin":156,"end":168},"obj":"http://purl.obolibrary.org/obo/GO_0009405"},{"id":"T11","span":{"begin":323,"end":344},"obj":"http://purl.obolibrary.org/obo/GO_0006486"},{"id":"T12","span":{"begin":659,"end":666},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T13","span":{"begin":789,"end":796},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T14","span":{"begin":1141,"end":1147},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T15","span":{"begin":1294,"end":1300},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T16","span":{"begin":1069,"end":1091},"obj":"http://purl.obolibrary.org/obo/GO_0006487"},{"id":"T17","span":{"begin":2099,"end":2106},"obj":"http://purl.obolibrary.org/obo/GO_0051923"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    GO-MF

    {"project":"GO-MF","denotations":[{"id":"T1","span":{"begin":572,"end":588},"obj":"http://purl.obolibrary.org/obo/GO_0005102"},{"id":"T2","span":{"begin":581,"end":588},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T3","span":{"begin":2107,"end":2114},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T4","span":{"begin":581,"end":588},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T5","span":{"begin":2107,"end":2114},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T6","span":{"begin":581,"end":588},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T7","span":{"begin":2107,"end":2114},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T8","span":{"begin":581,"end":588},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T9","span":{"begin":2107,"end":2114},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T10","span":{"begin":1894,"end":1902},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T11","span":{"begin":2091,"end":2114},"obj":"http://purl.obolibrary.org/obo/GO_0008201"},{"id":"T12","span":{"begin":2091,"end":2114},"obj":"http://purl.obolibrary.org/obo/GO_1904399"},{"id":"T13","span":{"begin":2091,"end":2114},"obj":"http://purl.obolibrary.org/obo/GO_0043395"},{"id":"T14","span":{"begin":2099,"end":2114},"obj":"http://purl.obolibrary.org/obo/GO_0043199"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    GO-CC

    {"project":"GO-CC","denotations":[{"id":"T1","span":{"begin":249,"end":253},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T2","span":{"begin":1379,"end":1383},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T3","span":{"begin":1617,"end":1621},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T4","span":{"begin":273,"end":278},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T5","span":{"begin":1846,"end":1858},"obj":"http://purl.obolibrary.org/obo/GO_0009986"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    EDAM-topics

    {"project":"EDAM-topics","denotations":[{"id":"T1","span":{"begin":127,"end":150},"obj":"http://edamontology.org/topic_0123"},{"id":"T2","span":{"begin":323,"end":330},"obj":"http://edamontology.org/topic_0078"},{"id":"T3","span":{"begin":628,"end":633},"obj":"http://edamontology.org/topic_3678"},{"id":"T4","span":{"begin":654,"end":666},"obj":"http://edamontology.org/topic_0749"},{"id":"T5","span":{"begin":741,"end":749},"obj":"http://edamontology.org/topic_0154"},{"id":"T6","span":{"begin":1286,"end":1293},"obj":"http://edamontology.org/topic_0154"},{"id":"T7","span":{"begin":1465,"end":1473},"obj":"http://edamontology.org/topic_0154"},{"id":"T8","span":{"begin":1507,"end":1515},"obj":"http://edamontology.org/topic_0154"},{"id":"T9","span":{"begin":1702,"end":1709},"obj":"http://edamontology.org/topic_0154"},{"id":"T10","span":{"begin":1710,"end":1718},"obj":"http://edamontology.org/topic_0080"},{"id":"T11","span":{"begin":1710,"end":1718},"obj":"http://edamontology.org/topic_3168"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    EDAM-DFO

    {"project":"EDAM-DFO","denotations":[{"id":"T1","span":{"begin":42,"end":51},"obj":"http://edamontology.org/operation_3432"},{"id":"T2","span":{"begin":127,"end":150},"obj":"http://edamontology.org/data_0897"},{"id":"T3","span":{"begin":254,"end":259},"obj":"http://edamontology.org/data_2100"},{"id":"T4","span":{"begin":323,"end":330},"obj":"http://edamontology.org/format_1208"},{"id":"T5","span":{"begin":323,"end":330},"obj":"http://edamontology.org/data_1467"},{"id":"T6","span":{"begin":499,"end":508},"obj":"http://edamontology.org/operation_3432"},{"id":"T7","span":{"begin":536,"end":542},"obj":"http://edamontology.org/data_2082"},{"id":"T8","span":{"begin":683,"end":692},"obj":"http://edamontology.org/operation_3432"},{"id":"T9","span":{"begin":741,"end":749},"obj":"http://edamontology.org/data_2906"},{"id":"T10","span":{"begin":852,"end":863},"obj":"http://edamontology.org/data_0977"},{"id":"T11","span":{"begin":852,"end":863},"obj":"http://edamontology.org/data_2576"},{"id":"T12","span":{"begin":855,"end":863},"obj":"http://edamontology.org/data_2611"},{"id":"T13","span":{"begin":855,"end":863},"obj":"http://edamontology.org/data_0842"},{"id":"T14","span":{"begin":931,"end":940},"obj":"http://edamontology.org/operation_0004"},{"id":"T15","span":{"begin":965,"end":973},"obj":"http://edamontology.org/operation_2945"},{"id":"T16","span":{"begin":1013,"end":1021},"obj":"http://edamontology.org/operation_3432"},{"id":"T17","span":{"begin":1286,"end":1293},"obj":"http://edamontology.org/data_2906"},{"id":"T18","span":{"begin":1384,"end":1408},"obj":"http://edamontology.org/data_0928"},{"id":"T19","span":{"begin":1465,"end":1473},"obj":"http://edamontology.org/data_2906"},{"id":"T20","span":{"begin":1507,"end":1515},"obj":"http://edamontology.org/data_2906"},{"id":"T21","span":{"begin":1622,"end":1627},"obj":"http://edamontology.org/data_2100"},{"id":"T22","span":{"begin":1702,"end":1709},"obj":"http://edamontology.org/data_2906"},{"id":"T23","span":{"begin":1710,"end":1718},"obj":"http://edamontology.org/operation_3218"},{"id":"T24","span":{"begin":1710,"end":1718},"obj":"http://edamontology.org/data_2044"},{"id":"T25","span":{"begin":1710,"end":1732},"obj":"http://edamontology.org/data_0854"},{"id":"T26","span":{"begin":1710,"end":1732},"obj":"http://edamontology.org/data_1014"},{"id":"T27","span":{"begin":1920,"end":1928},"obj":"http://edamontology.org/operation_2945"},{"id":"T28","span":{"begin":1996,"end":2010},"obj":"http://edamontology.org/data_2746"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    Lectin

    {"project":"Lectin","denotations":[{"id":"Lectin_T1","span":{"begin":369,"end":373},"obj":"https://acgg.asia/db/lfdb/LfDB0053"},{"id":"Lectin_T2","span":{"begin":599,"end":603},"obj":"https://acgg.asia/db/lfdb/LfDB0053"},{"id":"Lectin_T3","span":{"begin":654,"end":658},"obj":"https://acgg.asia/db/lfdb/LfDB0053"},{"id":"Lectin_T4","span":{"begin":944,"end":948},"obj":"https://acgg.asia/db/lfdb/LfDB0053"},{"id":"Lectin_T5","span":{"begin":999,"end":1003},"obj":"https://acgg.asia/db/lfdb/LfDB0053"},{"id":"Lectin_T6","span":{"begin":1452,"end":1456},"obj":"https://acgg.asia/db/lfdb/LfDB0053"},{"id":"Lectin_T7","span":{"begin":1502,"end":1506},"obj":"https://acgg.asia/db/lfdb/LfDB0053"},{"id":"Lectin_T8","span":{"begin":1774,"end":1778},"obj":"https://acgg.asia/db/lfdb/LfDB0053"},{"id":"Lectin_T9","span":{"begin":1873,"end":1877},"obj":"https://acgg.asia/db/lfdb/LfDB0053"},{"id":"Lectin_T10","span":{"begin":1966,"end":1970},"obj":"https://acgg.asia/db/lfdb/LfDB0053"},{"id":"Lectin_T11","span":{"begin":2125,"end":2129},"obj":"https://acgg.asia/db/lfdb/LfDB0053"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    GlycoBiology-Epitope

    {"project":"GlycoBiology-Epitope","denotations":[{"id":"PD-GlycoEpitope-B_T1","span":{"begin":2091,"end":2106},"obj":"http://www.glycoepitope.jp/epitopes/EP0086"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    GlyTouCan-IUPAC

    {"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T2","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T3","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T4","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T5","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T6","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T7","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T8","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T9","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T10","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T11","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T12","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T13","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T14","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T15","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T16","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T17","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T18","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T19","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T20","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T21","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T22","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T23","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T24","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T25","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T26","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T27","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T28","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T29","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T30","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T31","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T32","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T33","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T34","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T35","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T36","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T37","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T38","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T39","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T40","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T41","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T42","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T43","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T44","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T45","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T46","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T47","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T48","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T49","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T50","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T51","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T52","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T53","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T54","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T55","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T56","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T57","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T58","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T59","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T60","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T61","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T62","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T63","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T64","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T65","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T66","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T67","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T68","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T69","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T70","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T71","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T72","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T73","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T74","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T75","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T76","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T77","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T78","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T79","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T80","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T81","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T82","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T83","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T84","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T85","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T86","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T87","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T88","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T89","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T90","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T91","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T92","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T93","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T94","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T95","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T96","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T97","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T98","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T99","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T100","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T101","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T102","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T103","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T104","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T105","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T106","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T107","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T108","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T109","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T110","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T111","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T112","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T113","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T114","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T115","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T116","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T117","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T118","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T119","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T120","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T121","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T122","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T123","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T124","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T125","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T126","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T127","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T128","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T129","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T130","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T131","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T132","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T133","span":{"begin":827,"end":833},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T134","span":{"begin":1232,"end":1238},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T135","span":{"begin":1334,"end":1340},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T136","span":{"begin":1580,"end":1586},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T137","span":{"begin":1653,"end":1659},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T138","span":{"begin":2011,"end":2017},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T139","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G41652MJ\""},{"id":"GlycanIUPAC_T140","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G20761YC\""},{"id":"GlycanIUPAC_T141","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G19807HM\""},{"id":"GlycanIUPAC_T142","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G20351TE\""},{"id":"GlycanIUPAC_T143","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G71957MR\""},{"id":"GlycanIUPAC_T144","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G59040AE\""},{"id":"GlycanIUPAC_T145","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G14987PW\""},{"id":"GlycanIUPAC_T146","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G95064PC\""},{"id":"GlycanIUPAC_T147","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G39143AQ\""},{"id":"GlycanIUPAC_T148","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G65149OO\""},{"id":"GlycanIUPAC_T149","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G02766SY\""},{"id":"GlycanIUPAC_T150","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G26019KJ\""},{"id":"GlycanIUPAC_T151","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G36429CZ\""},{"id":"GlycanIUPAC_T152","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G89633TP\""},{"id":"GlycanIUPAC_T153","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G28494FO\""},{"id":"GlycanIUPAC_T154","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G06219CP\""},{"id":"GlycanIUPAC_T155","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G44237SM\""},{"id":"GlycanIUPAC_T156","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G57948RL\""},{"id":"GlycanIUPAC_T157","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G64016DN\""},{"id":"GlycanIUPAC_T158","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G14536PC\""},{"id":"GlycanIUPAC_T159","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G14356FW\""},{"id":"GlycanIUPAC_T160","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G34565UO\""},{"id":"GlycanIUPAC_T161","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G67124MW\""},{"id":"GlycanIUPAC_T162","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G71457ZU\""},{"id":"GlycanIUPAC_T163","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G55228VZ\""},{"id":"GlycanIUPAC_T164","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G31034MJ\""},{"id":"GlycanIUPAC_T165","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G25776IP\""},{"id":"GlycanIUPAC_T166","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G64442BV\""},{"id":"GlycanIUPAC_T167","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G57018LE\""},{"id":"GlycanIUPAC_T168","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G61761GX\""},{"id":"GlycanIUPAC_T169","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G76318UX\""},{"id":"GlycanIUPAC_T170","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G61906ER\""},{"id":"GlycanIUPAC_T171","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G68723GR\""},{"id":"GlycanIUPAC_T172","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G19540LE\""},{"id":"GlycanIUPAC_T173","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G74944PO\""},{"id":"GlycanIUPAC_T174","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G89489ZJ\""},{"id":"GlycanIUPAC_T175","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G04434YU\""},{"id":"GlycanIUPAC_T176","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G21450PB\""},{"id":"GlycanIUPAC_T177","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G93629QY\""},{"id":"GlycanIUPAC_T178","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G02603TR\""},{"id":"GlycanIUPAC_T179","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G40280JP\""},{"id":"GlycanIUPAC_T180","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G95259IC\""},{"id":"GlycanIUPAC_T181","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G26900FE\""},{"id":"GlycanIUPAC_T182","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G21346KK\""},{"id":"GlycanIUPAC_T183","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G62509FF\""},{"id":"GlycanIUPAC_T184","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G83932AK\""},{"id":"GlycanIUPAC_T185","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G96978IB\""},{"id":"GlycanIUPAC_T186","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G34275DN\""},{"id":"GlycanIUPAC_T187","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G07071JF\""},{"id":"GlycanIUPAC_T188","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G80639QD\""},{"id":"GlycanIUPAC_T189","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G99460PJ\""},{"id":"GlycanIUPAC_T190","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G22024BZ\""},{"id":"GlycanIUPAC_T191","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G74097ZY\""},{"id":"GlycanIUPAC_T192","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G84439YP\""},{"id":"GlycanIUPAC_T193","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G52207WQ\""},{"id":"GlycanIUPAC_T194","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G90695MS\""},{"id":"GlycanIUPAC_T195","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G50398QX\""},{"id":"GlycanIUPAC_T196","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G12166ZT\""},{"id":"GlycanIUPAC_T197","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G48368BR\""},{"id":"GlycanIUPAC_T198","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G57407RW\""},{"id":"GlycanIUPAC_T199","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G00386TY\""},{"id":"GlycanIUPAC_T200","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G18723JK\""},{"id":"GlycanIUPAC_T201","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G93757OR\""},{"id":"GlycanIUPAC_T202","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G29006SI\""},{"id":"GlycanIUPAC_T203","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G03099OQ\""},{"id":"GlycanIUPAC_T204","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G53739OW\""},{"id":"GlycanIUPAC_T205","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G70440ZO\""},{"id":"GlycanIUPAC_T206","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G29951RR\""},{"id":"GlycanIUPAC_T207","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G58402TI\""},{"id":"GlycanIUPAC_T208","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G39875TP\""},{"id":"GlycanIUPAC_T209","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G83439QV\""},{"id":"GlycanIUPAC_T210","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G41762RC\""},{"id":"GlycanIUPAC_T211","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G91604UI\""},{"id":"GlycanIUPAC_T212","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G88447WE\""},{"id":"GlycanIUPAC_T213","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G93634BS\""},{"id":"GlycanIUPAC_T214","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G02587BH\""},{"id":"GlycanIUPAC_T215","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G43511MX\""},{"id":"GlycanIUPAC_T216","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G64958DH\""},{"id":"GlycanIUPAC_T217","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G30384TR\""},{"id":"GlycanIUPAC_T218","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G15624EX\""},{"id":"GlycanIUPAC_T219","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G22706ST\""},{"id":"GlycanIUPAC_T220","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G57408PI\""},{"id":"GlycanIUPAC_T221","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G86403XX\""},{"id":"GlycanIUPAC_T222","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G78043YB\""},{"id":"GlycanIUPAC_T223","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G18952JK\""},{"id":"GlycanIUPAC_T224","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G49020ND\""},{"id":"GlycanIUPAC_T225","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G63590YW\""},{"id":"GlycanIUPAC_T226","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G22793KS\""},{"id":"GlycanIUPAC_T227","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G64134SS\""},{"id":"GlycanIUPAC_T228","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G17338HY\""},{"id":"GlycanIUPAC_T229","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G99745XF\""},{"id":"GlycanIUPAC_T230","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G27782HN\""},{"id":"GlycanIUPAC_T231","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G57496DC\""},{"id":"GlycanIUPAC_T232","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G93169WB\""},{"id":"GlycanIUPAC_T233","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G05518TD\""},{"id":"GlycanIUPAC_T234","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G62603DN\""},{"id":"GlycanIUPAC_T235","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G59574FS\""},{"id":"GlycanIUPAC_T236","span":{"begin":1571,"end":1574},"obj":"\"http://rdf.glycoinfo.org/glycan/G47567WC\""}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    performance-test

    {"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":282,"end":289},"obj":"http://purl.obolibrary.org/obo/UBERON_2000602"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    mondo_disease

    {"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":72,"end":86},"obj":"Disease"},{"id":"T2","span":{"begin":172,"end":186},"obj":"Disease"},{"id":"T3","span":{"begin":231,"end":240},"obj":"Disease"},{"id":"T4","span":{"begin":1791,"end":1800},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0004609"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0004609"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    NCBITAXON

    {"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":79,"end":92},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":179,"end":192},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"10294"},{"id":"A2","pred":"db_id","subj":"T2","obj":"10294"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    Glycosmos15-GlycoEpitope

    {"project":"Glycosmos15-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":2091,"end":2106},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A1","pred":"glycoepitope_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/EP0086"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    Anatomy-UBERON

    {"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":79,"end":86},"obj":"Body_part"},{"id":"T2","span":{"begin":179,"end":186},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0005350"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0005350"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}

    Glycosmos15-CL

    {"project":"Glycosmos15-CL","denotations":[{"id":"T1","span":{"begin":282,"end":289},"obj":"Cell"}],"attributes":[{"id":"A1","pred":"cl_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL:0000540"}],"text":"Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.\nThe pathogenesis of herpes simplex virus type 1 (HSV-1) implies the sequential infection of many cell types from mucosal cells to neurons, each having a unique pattern of protein glycosylation. The HSV-1 glycoprotein gC-1 is highly glycosylated and contains not only N-linked glycans but also a large number of O-linked glycans, some of which are clustered into two pronase-resistant arrays in the vicinity of the HSV-1 receptor-binding domain of gC-1. The aim of the present study was to characterize gC-1 signals for addition of clustered glycans, to determine the efficacy of synthetic peptides, representing putative O-glycosylation signals, as substrates for a panel of GalNAc transferases, and to identify possible effects of early O-linked glycosylation on the biological functions of gC-1. Gel filtration analysis of the pronase-resistant gC-1 O-glycan clusters from a glycoprotein mutant, lacking a site for N-linked glycosylation at Asn 73 in the vicinity of the O-glycosylation signal, suggested that one function of this N-linked glycan was to modulate the access for GalNAc transferases to one particular O-glycosylation peptide signal (aa 80-104). The ability of four GalNAc-transferase isoenzymes with different cell type expression patterns to initialize O-glycosylation of synthetic gC-1 derived peptides was analyzed. Two synthetic gC-1 peptides (aa 55-69 and aa 80-104) were excellent substrates for all four GalNAc-transferases, suggesting that cell types expressing less frequent GalNAc transferase species with unusual acceptor peptide sequence specificities may also produce a highly O-glycosylated gC-1 after HSV-1 infection. The O-linked glycans were not essential for cell surface expression of gC-1, but monoclonal antibody-assisted epitope analysis of N-acetylgalactosaminidase-treated gC-1 showed that the O-linked monosaccharide GalNAc contributed to expression of a three-dimensional epitope overlapping the heparan sulfate-binding domain of gC-1."}